Pharmacogenomics of Insulin Secretagogues in Pharmacodynamics, Pharmacokinetics and Adverse Reactions

Insulin secretagogues, including sulfonylureas and glinides, are prevailingly used to manage type 2 diabetes mellitus to ameliorate hyperglycemia. Although they have been wildly used in clinic for many years and exhibited acceptable efficacy, however, the response to these drugs varies among individuals, which is partly due to the genetic factors that affect the pharmacokinetics, pharmacodynamics and adverse reactions of the drugs. Pharmacogenomics, is to expound the relationship between the genetic polymorphisms and drug responses, which is expected to provide information for personalized medicing. In this article, we review and discuss current pharmacogenomics researches on insulin secretagogues, and wish to provide useful data and idea to improve the utilization of these drugs in clinic.